Logo
x

Search

Subscribe Now

Regeneron

Regeneron and Sanofi Report the EC’s Approval of Dupixent to Treat Chronic Obstructive Pulmonary Disease (COPD)

Regeneron and Sanofi Report the EC’s Approval of Dupixent to Treat Chronic Obstructive Pulmonary Disease (COPD)

  • July 3, 2024
Regeneron’s Ordspono Gains the CHMP’s Positive Opinion to Treat r/r Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Regeneron’s Ordspono Gains the CHMP’s Positive Opinion to Treat r/r Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLB...

  • June 28, 2024
Regeneron Showcases Updated P-I/II (LINKER-MM1) Study Data of Linvoseltamab for Treating R/R Multiple Myeloma at EHA 2024

Regeneron Showcases Updated P-I/II (LINKER-MM1) Study Data of Linvoseltamab for Treating R/R Multiple Myeloma at EHA 2024

  • June 17, 2024
Regeneron’s Kevzara (Sarilumab) Gains the US FDA’s Approval to Treat Active Polyarticular Juvenile Idiopathic Arthritis (PJIA)

Regeneron’s Kevzara (Sarilumab) Gains the US FDA’s Approval to Treat Active Polyarticular Juvenile Idiopathic Arthritis (PJIA)

  • June 11, 2024
Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent to Treat Chronic Rhinosinusitis with Nasal Polyposis (CRSWNP)

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance of Dupixent to Treat Chronic Rhinosinusitis with Nasal Polyposis (CRSWNP)

  • May 13, 2024
Regeneron Reports Results from the P-I/II (CHORD) Study of DB-OTO for Hearing Loss

Regeneron Reports Results from the P-I/II (CHORD) Study of DB-OTO for Hearing Loss

  • May 9, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.